Noriko Kohyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noriko Kohyama has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Mari Kogo
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, Tokyo, Japan
7 shared publications - Miki Takenaka Sato
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
5 shared publications - Jun Morita
Department of Urology, Showa Medical University Hospital, Tokyo, Japan
3 shared publications - Masayuki Ohbayashi
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
3 shared publications - Yoshio Ogawa
Department of Urology, Showa Medical University Hospital, Tokyo, Japan
3 shared publications - Erika Iwasaki
Department of Hospital Pharmaceutics, Showa Medical University School of Pharmacy, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 5 March 2026
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 31
Factors Associated With Loop Diuretic De-escalation in Patients With Acute Decompensated Heart Failure: The Influence of Guideline Directed Medical Therapy Initiation
Background: In patients with heart failure (HF), loop diuretics (LD) are recommended to relieve congestion and may be de-escalated if symptoms improve. However, long-term use of the same LD dose is sometimes required owing to potential congestion exacerbation. Therefore, we investigated the factors associated with LD de-escalation in patients with acute decompensated HF (ADHF) and the relationship between this de-escalation and initiating guideline directed medical therapy (GDMT) during hospitalization. Methods: In this retrospective cohort study, patients with ADHF who were prescribed LD and GDMT at discharge were included. The primary endpoint was LD de-escalation at 6 months post-discharge. Factors associated with this de-escalation were extracted using multivariate analysis. The Cochran–Armitage trend test was used to analyze the relationship between the number of GDMT initiated during hospitalization and LD de-escalation. Results: Of 193 eligible patients, 40.4% underwent LD de-escalation. Significant de-escalation-associated factors were age 2 (2.022; 1.073-3.811), and no atrial fibrillation (1.948; 1.047-3.625). The LD de-escalation rate tended to increase with the number of angiotensin receptor-neprilysin inhibitor, mineralocorticoid receptor antagonists, and sodium-glucose transporter 2 inhibitors initiated during hospitalization ( P = .013). Conclusion: Younger age, high BMI, and no atrial fibrillation were LD de-escalation-associated factors in patients with ADHF. LD de-escalation post-discharge may occur more frequently if the number of GDMT with diuretic effects was increased during hospitalization.
- 5 March 2026
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 31
Open AccessFactors Associated With Loop Diuretic De-escalation in Patients With Acute Decompensated Heart Failure: The Influence of Guideline Directed Medical Therapy Initiation
Background: In patients with heart failure (HF), loop diuretics (LD) are recommended to relieve congestion and may be de-escalated if symptoms improve. However, long-term use of the same LD dose is sometimes required owing to potential congestion exacerbation. Therefore, we investigated the factors associated with LD de-escalation in patients with acute decompensated HF (ADHF) and the relationship between this de-escalation and initiating guideline directed medical therapy (GDMT) during hospitalization. Methods: In this retrospective cohort study, patients with ADHF who were prescribed LD and GDMT at discharge were included. The primary endpoint was LD de-escalation at 6 months post-discharge. Factors associated with this de-escalation were extracted using multivariate analysis. The Cochran–Armitage trend test was used to analyze the relationship between the number of GDMT initiated during hospitalization and LD de-escalation. Results: Of 193 eligible patients, 40.4% underwent LD de-escalation. Significant de-escalation-associated factors were age 2 (2.022; 1.073-3.811), and no atrial fibrillation (1.948; 1.047-3.625). The LD de-escalation rate tended to increase with the number of angiotensin receptor-neprilysin inhibitor, mineralocorticoid receptor antagonists, and sodium-glucose transporter 2 inhibitors initiated during hospitalization ( P = .013). Conclusion: Younger age, high BMI, and no atrial fibrillation were LD de-escalation-associated factors in patients with ADHF. LD de-escalation post-discharge may occur more frequently if the number of GDMT with diuretic effects was increased during hospitalization.
- Open Access
- 9 November 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 269, 117242
Development of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin
- 9 November 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 269, 117242
Open AccessDevelopment of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin
- Open Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2349-2360
Factors Associated with Initial Treatment Failure in Inpatients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Cohort Study
Purpose: Some patients do not respond to initial therapy for exacerbation of chronic obstructive pulmonary disease (ECOPD), resulting in treatment failure that requires antimicrobial changes or advanced therapies. Appropriate treatment is possible if patients at a high risk of treatment failure at the start of treatment are properly identified. Therefore, this study examined the factors associated with initial treatment failure in patients with ECOPD. Patients and Methods: We conducted a cohort study involving patients with ECOPD admitted to our hospital. The primary outcome was initial treatment failure, defined as a composite of treatment intensification for ECOPD and in-hospital mortality. Uni- and multivariate analyses were performed to identify the factors associated with initial treatment failure. Results: The analysis included data of 152 patients with a mean age of 76± 8 years (mean±standard deviation); 81% of them were male patients. Treatment failure occurred in 26 (17%) patients. These included nine, two, one, and 14 patients who changed antimicrobial agents, received additional non-invasive positive pressure ventilation therapy due to non-improvement or symptom exacerbation, received additional invasive positive pressure ventilation therapy, and died in the hospital, respectively. Using multivariable analysis, home oxygen therapy (odds ratio, 5.335; 95% confidence interval, [1.542– 18.457]), neutrophil count ≥ 7000 cells/μL (3.550; [1.007– 12.519]), and acidemia (3.129; [1.009– 9.698]) were significant factors associated with treatment failure. In patients treated with narrow-spectrum antibiotics as the initial antibacterial therapy, the treatment failure rate in patients receiving home oxygen therapy was significantly higher than in those receiving none. Conclusion: Home oxygen therapy, high neutrophil count, and acidemia on admission were risk factors for treatment failure. Particularly, patients receiving home oxygen therapy were at a higher risk of treatment failure with the use of narrow-spectrum antibiotics.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2349-2360
Open AccessFactors Associated with Initial Treatment Failure in Inpatients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Cohort Study
Purpose: Some patients do not respond to initial therapy for exacerbation of chronic obstructive pulmonary disease (ECOPD), resulting in treatment failure that requires antimicrobial changes or advanced therapies. Appropriate treatment is possible if patients at a high risk of treatment failure at the start of treatment are properly identified. Therefore, this study examined the factors associated with initial treatment failure in patients with ECOPD. Patients and Methods: We conducted a cohort study involving patients with ECOPD admitted to our hospital. The primary outcome was initial treatment failure, defined as a composite of treatment intensification for ECOPD and in-hospital mortality. Uni- and multivariate analyses were performed to identify the factors associated with initial treatment failure. Results: The analysis included data of 152 patients with a mean age of 76± 8 years (mean±standard deviation); 81% of them were male patients. Treatment failure occurred in 26 (17%) patients. These included nine, two, one, and 14 patients who changed antimicrobial agents, received additional non-invasive positive pressure ventilation therapy due to non-improvement or symptom exacerbation, received additional invasive positive pressure ventilation therapy, and died in the hospital, respectively. Using multivariable analysis, home oxygen therapy (odds ratio, 5.335; 95% confidence interval, [1.542– 18.457]), neutrophil count ≥ 7000 cells/μL (3.550; [1.007– 12.519]), and acidemia (3.129; [1.009– 9.698]) were significant factors associated with treatment failure. In patients treated with narrow-spectrum antibiotics as the initial antibacterial therapy, the treatment failure rate in patients receiving home oxygen therapy was significantly higher than in those receiving none. Conclusion: Home oxygen therapy, high neutrophil count, and acidemia on admission were risk factors for treatment failure. Particularly, patients receiving home oxygen therapy were at a higher risk of treatment failure with the use of narrow-spectrum antibiotics.
- Open Access
- 26 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-10
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.
- 26 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-10
Open AccessVariations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.
- Open Access
- 4 September 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (4) , 301-310
Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure
Background: Sacubitril/valsartan (SV) is recommended for patients with heart failure (HF). In addition, a combination of 4 HF medications, including SV, is recommended in patients with HF with reduced ejection fraction (HFrEF). However, evidence on the characteristics of patients who could continue SV and its initiation methods is limited. Objective: To investigate the factors associated with SV continuation and methods of combining HF medications. Methods: This retrospective cohort study included HF patients who initiated with SV at our institution. The endpoint was SV continuation for 6 months after its initiation. Multivariate analysis was used to extract factors associated with SV continuation. The relationship between the methods of combining HF medications (renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, or sodium-glucose cotransporter 2 inhibitors), including the number of HF medications, their combination patterns, and the timing of their initiation, and SV continuation was examined in patients with HFrEF. Results: Of 186 eligible patients, 68.8% had HFrEF, and 79.0% continued SV for 6 months. Significant factors associated with SV continuation were albumin ≥ 3.5 g/dL (odds ratio, 4.81; 95% confidence interval, 2.19-10.59), body mass index (BMI) ≥ 18.5 kg/m 2 (4.17; 1.10-15.85), and systolic blood pressure (SBP) ≥ 110 mmHg (2.66; 1.12-6.28). In patients with HFrEF, the proportion of HF medications not initiated simultaneously with SV was significantly higher in the continuation group than in the discontinuation group (67.3% vs 33.3%, P = 0.002). The number of HF medications and their combination patterns were not significantly associated with SV continuation. Conclusion and Relevance: Albumin, BMI, and SBP are useful indicators for selecting patients who are likely to continue SV. In addition, initiating only SV without simultaneously initiating other HF medications in patients with HFrEF may lead to SV continuation.
- 4 September 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (4) , 301-310
Open AccessFactors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure
Background: Sacubitril/valsartan (SV) is recommended for patients with heart failure (HF). In addition, a combination of 4 HF medications, including SV, is recommended in patients with HF with reduced ejection fraction (HFrEF). However, evidence on the characteristics of patients who could continue SV and its initiation methods is limited. Objective: To investigate the factors associated with SV continuation and methods of combining HF medications. Methods: This retrospective cohort study included HF patients who initiated with SV at our institution. The endpoint was SV continuation for 6 months after its initiation. Multivariate analysis was used to extract factors associated with SV continuation. The relationship between the methods of combining HF medications (renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, or sodium-glucose cotransporter 2 inhibitors), including the number of HF medications, their combination patterns, and the timing of their initiation, and SV continuation was examined in patients with HFrEF. Results: Of 186 eligible patients, 68.8% had HFrEF, and 79.0% continued SV for 6 months. Significant factors associated with SV continuation were albumin ≥ 3.5 g/dL (odds ratio, 4.81; 95% confidence interval, 2.19-10.59), body mass index (BMI) ≥ 18.5 kg/m 2 (4.17; 1.10-15.85), and systolic blood pressure (SBP) ≥ 110 mmHg (2.66; 1.12-6.28). In patients with HFrEF, the proportion of HF medications not initiated simultaneously with SV was significantly higher in the continuation group than in the discontinuation group (67.3% vs 33.3%, P = 0.002). The number of HF medications and their combination patterns were not significantly associated with SV continuation. Conclusion and Relevance: Albumin, BMI, and SBP are useful indicators for selecting patients who are likely to continue SV. In addition, initiating only SV without simultaneously initiating other HF medications in patients with HFrEF may lead to SV continuation.
- Open Access
- 24 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-13
Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma
Background: The association between the combination of platelet count and neutrophil–lymphocyte ratio (COP-NLR) at the time of adverse events during sunitinib treatment and prognosis is unclear, and prognostic models combining the prognostic factors of sunitinib have not been well studied. Thus, we developed a prognostic model that includes the COP-NLR to predict the prognosis of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Methods: We performed a retrospective cohort study of 102 patients treated with sunitinib for mRCC between 2008 and 2020 in three hospitals associated with Showa University, Japan. The primary outcome was overall survival (OS). The collected data included baseline patient characteristics, adverse events, laboratory values, and COP-NLR scores within the first 6 weeks of sunitinib treatment. Prognostic factors of OS were analyzed using the Cox proportional hazards model. The integer score was derived from the beta-coefficient (β) of these factors and was divided into three groups. The survival curves were visualized using the Kaplan–Meier method and estimated using a log-rank test. Results: The median OS was 32.3 months. Multivariable analysis showed that the number of metastatic sites, Memorial Sloan Kettering Cancer Center risk group, number of metastases, non-hypertension, modified Glasgow Prognostic Score, and 6-week COP-NLR were significantly associated with OS. A higher 6-week COP-NLR was significantly associated with a shorter OS (p < 0.001). The β values of the five factors for OS were scored (non-hypertension, mGPS, and 6-week COP-NLR = 1 point; number of metastatic sites = 2 points; MSKCC risk group = 3 points) and patients divided into three groups (≤ 1, 2–3, and ≥ 4). The low-risk (≤ 1) group had significantly longer OS than the high-risk (≥ 4) group (median OS: 99.0 vs. 6.2 months, p < 0.001). Conclusions: This study showed that the COP-NLR within the first 6 weeks of sunitinib treatment had a greater impact on OS than the COP-NLR at the start of sunitinib treatment. The developed prognostic model for OS, including the 6-week COP-NLR, will be useful in decision-making to continue sunitinib in the early treatment stage of patients with mRCC.
- 24 November 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-13
Open AccessPrognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma
Background: The association between the combination of platelet count and neutrophil–lymphocyte ratio (COP-NLR) at the time of adverse events during sunitinib treatment and prognosis is unclear, and prognostic models combining the prognostic factors of sunitinib have not been well studied. Thus, we developed a prognostic model that includes the COP-NLR to predict the prognosis of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Methods: We performed a retrospective cohort study of 102 patients treated with sunitinib for mRCC between 2008 and 2020 in three hospitals associated with Showa University, Japan. The primary outcome was overall survival (OS). The collected data included baseline patient characteristics, adverse events, laboratory values, and COP-NLR scores within the first 6 weeks of sunitinib treatment. Prognostic factors of OS were analyzed using the Cox proportional hazards model. The integer score was derived from the beta-coefficient (β) of these factors and was divided into three groups. The survival curves were visualized using the Kaplan–Meier method and estimated using a log-rank test. Results: The median OS was 32.3 months. Multivariable analysis showed that the number of metastatic sites, Memorial Sloan Kettering Cancer Center risk group, number of metastases, non-hypertension, modified Glasgow Prognostic Score, and 6-week COP-NLR were significantly associated with OS. A higher 6-week COP-NLR was significantly associated with a shorter OS (p < 0.001). The β values of the five factors for OS were scored (non-hypertension, mGPS, and 6-week COP-NLR = 1 point; number of metastatic sites = 2 points; MSKCC risk group = 3 points) and patients divided into three groups (≤ 1, 2–3, and ≥ 4). The low-risk (≤ 1) group had significantly longer OS than the high-risk (≥ 4) group (median OS: 99.0 vs. 6.2 months, p < 0.001). Conclusions: This study showed that the COP-NLR within the first 6 weeks of sunitinib treatment had a greater impact on OS than the COP-NLR at the start of sunitinib treatment. The developed prognostic model for OS, including the 6-week COP-NLR, will be useful in decision-making to continue sunitinib in the early treatment stage of patients with mRCC.
- 21 November 2022
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 45 (1) , 210-219
Development of a model predicting cardiac events in heart failure patients with decreased renal function: a retrospective study
Background Inappropriate and multiple medications affect the prognosis of patients with acute decompensated heart failure (ADHF). However, in ADHF patients with decreased renal function, there have been no reports on prognostic factors, including medication data, or models for predicting cardiac events. Aim To develop a model including medication data to predict cardiac events in ADHF patients with decreased renal function. Method This retrospective cohort study included 443 first-time admitted ADHF patients with decreased renal function (estimated glomerular filtration rate < 60 mL/min/1.73 m2 at discharge) in the Showa University Fujigaoka Hospital. The primary outcome was cardiac events within one year after discharge, defined as the composite of HF readmission, HF mortality, and cardiovascular mortality. The model for predicting cardiac events was developed using predictive factors extracted by multivariable analysis. The cardiac events curves were visualized using the Kaplan–Meier method and estimated using a log-rank test. Results The incidence of cardiac events within one year after discharge was 20.1%. By multivariable analysis, we observed that atrial fibrillation, weight loss < 5%, brain natriuretic peptide ≥ 200 pg/mL, polypharmacy, and beta-blockers use below target dosage were significantly associated with an increased risk of cardiac events. The developed model, the cardiac events rate in the high-risk group was significantly higher than in the low-risk group (41.0 vs. 9.2%, p < 0.001). Conclusion The developed model for predicting cardiac events will be useful in decision-making to support appropriate early management of ADHF patients with decreased renal function.
- 21 November 2022
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 45 (1) , 210-219
Development of a model predicting cardiac events in heart failure patients with decreased renal function: a retrospective study
Background Inappropriate and multiple medications affect the prognosis of patients with acute decompensated heart failure (ADHF). However, in ADHF patients with decreased renal function, there have been no reports on prognostic factors, including medication data, or models for predicting cardiac events. Aim To develop a model including medication data to predict cardiac events in ADHF patients with decreased renal function. Method This retrospective cohort study included 443 first-time admitted ADHF patients with decreased renal function (estimated glomerular filtration rate < 60 mL/min/1.73 m2 at discharge) in the Showa University Fujigaoka Hospital. The primary outcome was cardiac events within one year after discharge, defined as the composite of HF readmission, HF mortality, and cardiovascular mortality. The model for predicting cardiac events was developed using predictive factors extracted by multivariable analysis. The cardiac events curves were visualized using the Kaplan–Meier method and estimated using a log-rank test. Results The incidence of cardiac events within one year after discharge was 20.1%. By multivariable analysis, we observed that atrial fibrillation, weight loss < 5%, brain natriuretic peptide ≥ 200 pg/mL, polypharmacy, and beta-blockers use below target dosage were significantly associated with an increased risk of cardiac events. The developed model, the cardiac events rate in the high-risk group was significantly higher than in the low-risk group (41.0 vs. 9.2%, p < 0.001). Conclusion The developed model for predicting cardiac events will be useful in decision-making to support appropriate early management of ADHF patients with decreased renal function.
- Open Access
- 1 January 2021
- Published by The Showa University Society in The Showa University Journal of Medical Sciences
- Vol. 33 (2) , 55-64
Risk factors for initial antibiotic treatment failure in patients with aspiration pneumonia
Sulbactam/ampicillin (SBT/ABPC) and ceftriaxone (CTRX) are the initial antibiotics recommended for treating aspiration pneumonia without risk factors for drug-resistant pathogens. However, the condition of some patients does not improve with these antibiotics. Therefore, we investigated the new risk factors associated with failure of initial antibiotic treatment in patients with aspiration pneumonia. This study included 487 patients diagnosed with aspiration pneumonia who received initial antibiotic treatment with SBT/ABPC or CTRX, and were hospitalized at the Respiratory Medicine Department of the Yokohama City Minato Red Cross Hospital. The outcome was initial antibiotic treatment failure, which was defined as a change from initial to secondary antibiotic treatment. The characteristics of patients with and without antibiotic treatment failure were compared using univariate analyses, and significant independent risk factors for the initial antibiotic treatment failure were selected using multivariate analyses. The mean age of the patients was 84.1 ± 9.6 years; 302 (62%) of them were men and 93 patients experienced antibiotic treatment failure. Logistic regression analysis extracted no restriction of diet on admission (odds ratio [OR], 3.23; 95% confidence interval [CI], 1.35-7.74), history of hospitalization due to aspiration pneumonia (OR, 1.81; 95%CI, 1.12-2.93), the severity of pneumonia (OR, 1.37; 95%CI, 1.01-1.86), and C-reactive protein (CRP) level (OR, 1.26; 95%CI, 1.09-1.45) as risk factors for initial antibiotic treatment failure. Our results suggested that no restriction of diet on admission, history of hospitalization due to aspiration pneumonia, severity of pneumonia, and increased CRP levels were the risk factors associated with failure of initial antibiotic treatment in patients with aspiration pneumonia. These factors will be useful for determining an effective initial treatment strategy for patients with aspiration pneumonia.
- 1 January 2021
- Published by The Showa University Society in The Showa University Journal of Medical Sciences
- Vol. 33 (2) , 55-64
Open AccessRisk factors for initial antibiotic treatment failure in patients with aspiration pneumonia
Sulbactam/ampicillin (SBT/ABPC) and ceftriaxone (CTRX) are the initial antibiotics recommended for treating aspiration pneumonia without risk factors for drug-resistant pathogens. However, the condition of some patients does not improve with these antibiotics. Therefore, we investigated the new risk factors associated with failure of initial antibiotic treatment in patients with aspiration pneumonia. This study included 487 patients diagnosed with aspiration pneumonia who received initial antibiotic treatment with SBT/ABPC or CTRX, and were hospitalized at the Respiratory Medicine Department of the Yokohama City Minato Red Cross Hospital. The outcome was initial antibiotic treatment failure, which was defined as a change from initial to secondary antibiotic treatment. The characteristics of patients with and without antibiotic treatment failure were compared using univariate analyses, and significant independent risk factors for the initial antibiotic treatment failure were selected using multivariate analyses. The mean age of the patients was 84.1 ± 9.6 years; 302 (62%) of them were men and 93 patients experienced antibiotic treatment failure. Logistic regression analysis extracted no restriction of diet on admission (odds ratio [OR], 3.23; 95% confidence interval [CI], 1.35-7.74), history of hospitalization due to aspiration pneumonia (OR, 1.81; 95%CI, 1.12-2.93), the severity of pneumonia (OR, 1.37; 95%CI, 1.01-1.86), and C-reactive protein (CRP) level (OR, 1.26; 95%CI, 1.09-1.45) as risk factors for initial antibiotic treatment failure. Our results suggested that no restriction of diet on admission, history of hospitalization due to aspiration pneumonia, severity of pneumonia, and increased CRP levels were the risk factors associated with failure of initial antibiotic treatment in patients with aspiration pneumonia. These factors will be useful for determining an effective initial treatment strategy for patients with aspiration pneumonia.